Lessons from controversy: Ovarian cancer screening and serum proteomics

Journal of the National Cancer Institute

Volumn 97, Issue 4, 2005, Pages 315-319

  Ransohoff, David F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROTEOME; TUMOR MARKER;

ANALYTICAL ERROR; ARTICLE; BLOOD ANALYSIS; CANCER SCREENING; CLINICAL OBSERVATION; DIAGNOSTIC PROCEDURE; EVIDENCE BASED MEDICINE; MASS SPECTROMETRY; MEDICAL RESEARCH; METHODOLOGY; OVARY CANCER; PATTERN RECOGNITION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RELIABILITY; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; FEMALE; HUMAN; MASS SCREENING; METABOLISM; NOTE; OBSERVER VARIATION; OVARY TUMOR; STANDARD;

FEMALE; HUMANS; MASS SCREENING; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 13844322072     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji054     Document Type: Article

References (48)

1. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
2. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 2003;100:14666-71.
3. Marcus A. Testing for ovarian cancer is on the way. Wall St J, October 1,2002: D1, D2.
4. Pollack A. New cancer test stirs hope and concern. N York Times, February 3,2004:D1,D6.
5. Food and Drug Administration. Letter to Correlogic Systems, Inc., February 18, 2004. Available at: http://www.fda.gov/cdrh/oivd/letters/021804-correlogic.html. [Last accessed: January 14, 2005.]
6. Food and Drug Administration. Letter to Quest Diagnostics, March 2,2004. Available at: http://www.fda.gov/cdrh/oivd/letters/030204-quest.html. [Last accessed: January 14, 2005.]
7. Food and Drug Administration. Letter to Laboratory Corporation of America, March 2, 2004. Available at: http://www.fda.gov/cdrh/oivd/letters/030204-labcorp.html. [Last accessed: January 15, 2005.]
8. Wagner L. A test before its time? FDA stalls distribution process of proteomic test. J Natl Cancer Inst 2004;96:500-1.
9. Diamandis E. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96: 353-6.
10. Check E. Running before we can walk? Nature 2004;429:496-7.
11. Garber K. Debate rages over proteomic patterns. J Natl Cancer Inst 2004;96:816-8.
12. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomics tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
13. Liotta LA, Lowenthal M, Conrads TP, Veenstra TD, Fishman DA, Petricoin EF III. Misinformation generated by lack of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005;97:310-4.
14. Jasny BR, Roberts L. Solving gene expression. Science 2004;306:629.
15. Marshall E. Getting the noise out of gene arrays. Science 2004;306:630-1.
16. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-30.
17. Ransohoff DF. Challenges and opportunities in evaluating diagnostic tests. J Clin Epidemiol 2002;55:1178-82.
18. Potter JD. At the interfaces of epidemiology, genetics and genomics. Nat Rev Genet 2001;2:142-7.
19. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
20. Ransohoff DF. Developing molecular biomarkers for cancer. Science 2003;299:1679-80.
21. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
22. Ransohoff DF. Evaluating discovery-based research: when biologic reasoning cannot work. Gastroenterology 2004;127:1028.
23. Ransohoff DF. Bias as a threat to validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-9.
24. Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia (PA): WB Saunders, 1985.
25. Hennekens CH, Buring JE. Epidemiology in medicine. Boston (MA): Little, Brown, 1987.
26. Sackett DL, Haynes RB, Tugwell P, Guyatt GH. Clinical epidemiology: a basic science for clinical medicine. Boston (MA): Little, Brown, 1991.
27. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 3rd ed. Baltimore (MD): Williams & Wilkins, 1996.
28. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Designing clinical research: an epidemiologic approach. Philadelphia (PA): Lippincott Williams & Wilkins, 2001.
29. Sackett DL, Haynes RB. The architecture of diagnostic research. Br Med J 2002;324:539-41.
30. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8.
31. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
32. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
33. Ransohoff DF. Gene-expression signatures in breast cancer. N Engl J Med 2003;348:1715-7; author reply 1716-17.
34. Ransohoff DF. Discovery-based research and fishing. Gastroenterology 2003;125:290.
35. Piccart M, Loi S, van't Veer L, Saghatchian-d'Assignies M, Glass A, Ellis P, et al. Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Abstract presented at San Antonio Breast Cancer Symposium, December 8. Available at: http://www.abstracts2view.com/sabcs/search.php?queryxxxxxxx=Piccart& where=authors&intMaxHits=10&search=do. [Last accessed: December 23, 2004.]
36. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361: 1590-6.
37. Masters JR, Lakhani SR. How diagnosis with microarrays can help cancer patients. Nature 2000;404:921.
38. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
39. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003;362: 1439-44.
40. Taubes G. Epidemiology faces its limits [news] [see comments]. Science 1995;269:164-9.
41. Ransohoff DF. Research opportunity at the interface of molecular biology and clinical epidemiology. Gastroenterology 2002;122:1199.
42. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
43. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003;19:185-95.
44. Sackett DL. Zlinkoff honor lecture: basic research, clinical research, clinical epidemiology, and general internal medicine. J Gen Intern Med 1987;2: 40-7.
45. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 2002;99: 6562-6.
46. Baggerly KA, Morris JS, Wang J, Gold D, Xiao LC, Coombes KR. A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 2003;3:1667-72.
47. Mehta T, Tanik M, Allison DB. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nat Genet 2004;36:943-7.
48. Biomarkers and quality of care, key presentations at BSA meeting. NCI Cancer Bull, November 16, 2004;1:5.